It's completely understandable to feel anxious starting a new treatment, especially after reading through all those drug specifications — they can be pretty overwhelming! Venetoclax is a targeted therapy that works by blocking a protein that helps myeloma cells survive, essentially pushing those cells toward natural cell Show Full Answer
It's completely understandable to feel anxious starting a new treatment, especially after reading through all those drug specifications — they can be pretty overwhelming! Venetoclax is a targeted therapy that works by blocking a protein that helps myeloma cells survive, essentially pushing those cells toward natural cell death.
Here are the key risks and side effects to be aware of:
- Infections — This is one of the more serious risks, as Venetoclax can lower your white blood cell counts, making it harder to fight off infections
- Low blood cell counts — Including low red blood cells (anemia) and low platelets, which can cause fatigue and bleeding issues
- Tumor lysis syndrome (TLS) — A serious but manageable risk, especially early in treatment, where dying cancer cells release substances into the bloodstream too quickly
- Nausea, diarrhea, and fatigue — These are among the more common day-to-day side effects
- Blood clots — Particularly relevant when combined with dexamethasone
The good news is that your oncologist has kept Daratumumab and acyclovir in your regimen, which suggests they're being thoughtful about protecting you from certain risks like viral infections.
Always report any fever, unusual bruising, or breathing changes to your care team immediately. As for personal experiences, some MyMyelomaTeam members on relapsed myeloma have shared that starting a new regimen after a first-line treatment can feel daunting, but many find that their care team monitors them closely, especially in the early weeks.
It would be worth asking your oncologist specifically about TLS monitoring protocols and what warning signs to watch for at home. You're already ahead of the game by asking these questions!
July 24